ifinatamab deruxtecan + MK-5684

This is a combination of two investigational agents: **ifinatamab deruxtecan**, a first-in-class B7-H3–directed DXd antibody-drug conjugate (ADC), and **MK-5684** (also known as ODM-208), a first-in-class, oral, non-steroidal, selective inhibitor of the enzyme CYP11A1, which catalyzes the first step of steroid biosynthesis. Ifinatamab deruxtecan is engineered to deliver a topoisomerase I inhibitor payload specifically to B7-H3–expressing cancer cells, leading to targeted cell killing and minimizing off-target toxicity. MK-5684 suppresses synthesis of steroid hormones, thereby blocking androgen receptor (AR) pathway activation, which is key in prostate cancer and potentially other hormone-driven cancers. Both agents are being developed collaboratively by Daiichi Sankyo and Merck (MSD outside the US and Canada). The combination targets separate but potentially synergistic mechanisms in the treatment of cancers such as metastatic castration-resistant prostate cancer (mCRPC) and possibly others[1][2][3][5][6].

Other names

I-DXdODM-208ODM208ODM 208